Brain Metastases

Brain metastases are cancer tumors that began in another part of the body and spread to the brain. This is different from primary brain cancer, which starts in brain tissue. Brain mets can occur with several cancer types, including lung cancer, breast cancer, melanoma, kidney cancer and colorectal cancer. They may affect people whose cancer is newly diagnosed or has returned after earlier treatment.

Symptoms of metastatic brain cancer may develop gradually or appear suddenly. They depend on the tumor’s location, size, amount of swelling and number of tumors. Some people have no symptoms at first, while others notice changes in movement, thinking, sensation or alertness.

Malignant cells can break away from a primary tumor, enter blood vessels and travel to the brain. If they settle there and continue growing, they can form a metastatic tumor. The tumor usually retains important features of the original cancer, so treatment is guided by whether it began in the lung, breast, skin, kidney, colon or another organ.

The main risk is having a cancer that can spread to the brain. Risk is also influenced by the cancer’s biology, molecular features and extent, rather than by one lifestyle exposure. A risk factor increases the likelihood of brain spread but does not mean that it will definitely occur.

Complications depend on the tumor’s location, size, number and amount of swelling. They may also depend on bleeding or whether cancer affects the tissues or fluid around the brain and spinal cord. Treatment can cause additional effects, so the care team weighs symptom control against each therapy’s potential risks.

Report new or worsening neurological changes promptly. Treatment risks vary according to the therapy, your overall health and the location of the metastases, so ask the care team what symptoms require immediate attention.

Evaluation begins with a medical history and neurological examination. A contrast-enhanced brain MRI is a key imaging test, while CT may be used when MRI is not suitable or when rapid imaging is needed. Body imaging, laboratory tests and sometimes a biopsy can help identify the primary cancer or clarify an uncertain finding.

What clinicians assess

Clinicians assess the number, size and location of brain lesions, whether cancer is present elsewhere, the type and molecular features of the primary cancer, overall health and functional status. Brain metastases usually indicate advanced metastatic cancer; they are not assigned a separate stage I–IV system like a primary brain cancer.

Treatment for Brain Metastases is individualized according to the primary cancer, number and location of tumors, symptoms, previous treatment, molecular findings and overall goals of care. Local treatments for the brain may be combined with medicines that treat cancer throughout the body.

Treatment may aim to control tumors, preserve neurological function, relieve symptoms and support quality of life. It is not possible to promise a cure for every person, so a multidisciplinary oncology team should explain the likely benefits, risks and alternatives of an individualized plan.

The outlook varies widely. It depends on the original cancer, molecular features, number and location of brain metastases, cancer elsewhere in the body, response to treatment, overall health and access to effective therapies. Some people have durable control of brain lesions, while others have cancer that continues to progress despite treatment.

Questions that help clarify prognosis

Follow-up is individualized and may include scheduled brain MRI scans, visits with oncology and radiation or neurosurgical specialists, review of the primary cancer and monitoring for treatment effects or new neurological symptoms. The schedule may change if symptoms, imaging or the cancer’s response changes.